A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.
作者信息
Smith Emilie D, Ariane Vinson N, Zhong Desong, Berrang Bertold D, Catanzaro Jennifer L, Thomas James B, Navarro Hernán A, Gilmour Brian P, Deschamps Jeffrey, Carroll F Ivy
机构信息
Organic and Medicinal Chemistry, Research Triangle Institute, PO Box 12194, Research Triangle Park, NC 27709, USA.
出版信息
Bioorg Med Chem. 2008 Jan 15;16(2):822-9. doi: 10.1016/j.bmc.2007.10.023. Epub 2007 Oct 13.
Abstract
A new chiral synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (2, J-113397) was developed. J-113397 has a K(e)=0.85nM in an ORL-1 calcium mobilization assay and is 89-, 887-, and 227-fold selective for the ORL-1 receptor relative to the mu, delta, and kappa opioid receptors.
摘要
Zotero 插件